POLE mutation

News alerts, weekly reports and conference planners

Entrez ID:

5426

Related biomarkers:

Mutation

Others

‹

›

POLE mutation	Solid Tumor	POLE mutation	Solid Tumor	toripalimab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) toripalimab Sensitive : C2 ASCO-GI 2023 - 2wk	toripalimab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks toripalimab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
POLE mutation	Solid Tumor	POLE mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
POLE mutation	Endometrial Cancer	POLE mutation	Endometrial Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
POLE mutation	Gastric Cancer	POLE mutation	Gastric Cancer	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2
POLE mutation	Gastric Cancer	POLE mutation	Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
POLE mutation	Solid Tumor	POLE mutation	Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
POLE mutation	Endometrial Cancer	POLE mutation	Endometrial Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
POLE mutation	Colorectal Cancer	POLE mutation	Colorectal Cancer	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
POLE mutation	Solid Tumor	POLE mutation	Solid Tumor	dostarlimab Sensitive: C2 – Inclusion Criteria dostarlimab Sensitive : C2	dostarlimab Sensitive: C2 – Inclusion Criteria dostarlimab Sensitive : C2
POLE mutation	Melanoma	POLE mutation	Melanoma	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3
POLE mutation	Cholangiocarcinoma	POLE mutation	Cholangiocarcinoma	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3
POLE mutation	Non Small Cell Lung Cancer	POLE mutation	Non Small Cell Lung Cancer	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3
POLE mutation	Colorectal Cancer	POLE mutation	Colorectal Cancer	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + PD-L1 inhibitor Sensitive : C3
POLE mutation	Melanoma	POLE mutation	Melanoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
POLE mutation	Cholangiocarcinoma	POLE mutation	Cholangiocarcinoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
POLE mutation	Non Small Cell Lung Cancer	POLE mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
POLE mutation	Colorectal Cancer	POLE mutation	Colorectal Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
POLE mutation	Melanoma	POLE mutation	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
POLE mutation	Cholangiocarcinoma	POLE mutation	Cholangiocarcinoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
POLE mutation	Non Small Cell Lung Cancer	POLE mutation	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
POLE mutation	Colorectal Cancer	POLE mutation	Colorectal Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
POLE mutation	Colorectal Cancer	POLE mutation	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
POLE mutation	Gastroesophageal Cancer	POLE mutation	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
POLE mutation	Non Small Cell Lung Cancer	POLE mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
POLE mutation	Endometrial Cancer	POLE mutation	Endometrial Cancer	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4

POLE mutation

Associations